AU2025267445A1 — Compositions and methods for opioid antagonist delivery
Assigned to Purdue Pharma LP · Expires 2025-12-04 · 0y expired
What this patent protects
WO 2020/097068 PCT/US2019/059852 Disclosed in certain embodiments is a pharmaceutical formulation (e.g., parenteral formulation) comprising a therapeutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable adjuvant (e.…
USPTO Abstract
WO 2020/097068 PCT/US2019/059852 Disclosed in certain embodiments is a pharmaceutical formulation (e.g., parenteral formulation) comprising a therapeutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable adjuvant (e.g., parenterally acceptable adjuvant) that promotes the rate at which the nalmefene or salt thereof is more rapidly absorbed into the systemic circulation of a subject identified as in need thereof. 20 25 26 74 45 14 N ov 2 02 5 W O 2 0 2 0 / 0 9 7 0 6 8 P C T / U S 2 0 1 9 / 0 5 9 8 5 2 2 0 2 5 2 6 7 4 4 5 1 4 N o v 2 0 2 5
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.